Vildagliptin Worksheet

What is the recommended daily dose of Vildagliptin for most patients?

• 25 mg once daily

• 50 mg once daily

• 100 mg (50 mg twice daily)

• 200 mg once daily

What is a key advantage of Vildagliptin over Sitagliptin?

• Higher risk of hypoglycemia

• Complete DPP-4 inhibition for 24 hours

• Requires dose adjustment in renal impairment

• Higher cost

In which patient population is Jalra OD specifically indicated?

• Newly diagnosed T2DM

• T2DM uncontrolled on dual/triple therapy or insulin

• Prediabetes

• Type 1 diabetes

What is a unique feature of Jalra OD’s formulation?

• Immediate release of Vildagliptin

• Sustained-release polymer matrix for controlled drug delivery

• Contains SGLT2 inhibitor

• Requires refrigeration

Which parameter is improved with Vildagliptin 100 mg SR OD compared to Sitagliptin?

• QTc prolongation

• Time in range (TIR) by 3 hours

• Weight gain

• Liver enzyme elevation

What is the renal safety profile of Vildagliptin?

• Contraindicated in all renal impairment

• No dose adjustment needed even in severe renal impairment

• Requires halving the dose in mild impairment

• Only safe in dialysis patients

What is the MRP of Jalra 50 mg (pack of 30 tablets)?

• Rs 450

• Rs 660

• Rs 800

• Rs 199

What is the CV safety profile of Vildagliptin?

• Increases heart failure risk

• CV neutral with robust evidence

• Requires additional CV safety trials

• Contraindicated in ASCVD

Which statement about Jalra OD’s bioequivalence is correct?

• It is bioequivalent to Vildagliptin 50 mg IR twice daily.

• It has higher peak concentration than IR formulation.

In which population should Vildagliptin be avoided?

• Elderly patients

• Patients with liver impairment

• Patients with hypertension

• Patients with obesity